Digital Biomarkers and Artificial Intelligence for Early Detection and Risk Prediction of Diabetes-Associated Ocular Complications: Current Advances and Future Perspectives
Health Innovation Reports · 15.10.2026 · 2 (4) · 88-113
DOI: 10.64048/hir.v2n4.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Innovation Reports, online erschienen am 15.10.2026. Verfasst von Md. Al Amin. Die Arbeit nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Künstliche Intelligenz in der Pflege, Diabetes mellitus
Abstract (Originalsprache)
Introduction
Diabetes-associated ocular complications, including diabetic retinopathy (DR), diabetic macular edema (DME), retinal neurodegeneration and ocular surface abnormalities, are major causes of visual impairment. Digital biomarkers combined with artificial intelligence (AI) offer promising opportunities for early detection, disease monitoring and individualized risk prediction.
Methods
A structured literature search was conducted using PubMed, Scopus, Web of Science and Google Scholar. A total of 289 records were identified, of which 136 studies were included following duplicate removal, screening and full-text eligibility assessment. Relevant evidence on digital biomarkers, AI technologies, clinical applications, limitations and future perspectives was critically reviewed.
Findings
Digital biomarkers derived from fundus photography, optical coherence tomography (OCT), OCT angiography (OCTA), retinal electrophysiology and ocular surface imaging provide quantitative information about structural, vascular and functional abnormalities. Machine learning, deep learning and multimodal AI approaches demonstrate considerable potential for automated disease detection, severity classification and progression prediction. Longitudinal models, including DeepDR Plus, further support individualized screening strategies. AI-enabled clinical decision support may improve referral prioritization, treatment monitoring and ophthalmic care accessibility. However, dataset limitations, class imbalance, image quality, population bias, limited interpretability, inadequate external validation, privacy concerns and implementation costs remain important challenges.
Conclusion
Integrating digital biomarkers with AI may transform diabetes-associated ocular care by enabling earlier detection, personalized risk assessment and more efficient clinical decision-making. Future research should prioritize multimodal integration, longitudinal validation, explainable algorithms and affordable implementation in resource-limited healthcare settings.
Zitieren
APA
Amin, M. A. (2026). Digital Biomarkers and Artificial Intelligence for Early Detection and Risk Prediction of Diabetes-Associated Ocular Complications: Current Advances and Future Perspectives. Health Innovation Reports, 2(4), 88-113. https://doi.org/10.64048/hir.v2n4.011
Vancouver
Amin MA. Digital Biomarkers and Artificial Intelligence for Early Detection and Risk Prediction of Diabetes-Associated Ocular Complications: Current Advances and Future Perspectives. Health Innovation Reports. 2026;2(4):88-113. doi:10.64048/hir.v2n4.011
BibTeX
@article{Amin2026,
author = {Amin, Md. Al},
title = {Digital Biomarkers and Artificial Intelligence for Early Detection and Risk Prediction of Diabetes-Associated Ocular Complications: Current Advances and Future Perspectives},
journal = {Health Innovation Reports},
year = {2026},
volume = {2},
number = {4},
pages = {88--113},
doi = {10.64048/hir.v2n4.011}
}
EUVIMED